Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
12
12 articles ont été cités au moins 12fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
622
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
77
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
15
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Régional et Universitaire de Nancy
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Laminopathies: natural history and risk prediction of heart failure
2026ArticleEuropean Heart Journal
Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study
2026ArticleArchives of cardiovascular diseases
Prevalence and predictors of uncommon features in FSHD1 patients: insights from the French FSHD registry
2025ArticleOrphanet Journal of Rare Diseases
Nationwide Phenotypic and Genotypic Characterisation of 103 Patients With <i>SH3TC2</i> Gene‐Related Demyelinating Peripheral Neuropathy
2025ArticleEuropean Journal of Neurology
Spinal muscular atrophy is also a disorder of spermatogenesis
2024ArticleOrphanet Journal of Rare Diseases
Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis
2024ArticleBrain - A Journal of Neurology
Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments
2024ArticleOrphanet Journal of Rare Diseases
Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome
2024ArticleJournal of Neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHRU NANCY - HOPITAL CENTRAL
29 AV DE LATTRE DE TASSIGNY CO 60034, 54035 NANCY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of autoimmunity · 2018
Rheumatology (Oxford, England) · 2023
AbstractObjectivesExcessive and inappropriate production of pro-inflammatory cytokines plays a key role in Still’s disease. Janus kinase inhibitor (JAKi) agents mainly block pro-inflammatory cytokine pathways, notably IL-6 and IFN. The objective was to assess the efficacy and safety of JAKi agents in difficult-to-treat systemic JIA or adult-onset Still’s disease (AOSD).MethodsThis retrospective study was based on a national survey conducted in the departments of rheumatology, paediatric rheumatology and internal medicine of French hospitals regarding systemic JIA and AOSD patients who received JAKi agents. The data were collected with a standardized questionnaire and analysed at different times (treatment initiation, months 1, 3 and 6 and the end of follow-up).ResultsNine patients (seven adults) were included. All patients showed inadequate response to CS or conventional synthetic or biologic DMARDs. Baricitinib was used in five patients, ruxolitinib in two, tofacitinib in two and upadacitinib in one. A JAKi was used combined with CS in all but two patients. A JAKi was associated with anakinra and CS in one patient, and with MTX, anakinra and CS in another. The median (range) follow-up was 16 (1–33) months. Two cases out of nine showed complete remission, 3/9 partial response and 4/9 treatment failure. At the last visit, CS could be decreased but not stopped. Tolerance of the JAKi was acceptable (no severe adverse events).ConclusionJAKi agents may be a therapeutic option for some patients with difficult-to-treat Still’s disease, especially those with partial response to medium- or high-dose CS or biologics.
Arthritis research & therapy · 2021
Abstract Background Systemic sclerosis (SSc) is associated with a variability of mortality rates in the literature. Objective To determine the mortality and its predictors in a long-term follow-up of a bi-centric cohort of SSc patients. Methods A retrospective observational study by systematically analyzing the medical records of patients diagnosed with SSc in Toulouse University Hospital and Ducuing Hospital. Standardized Mortality Ratio (SMR), mortality at 1, 3, 5, 10, and 15 years of disease and causes of death were described. Predictors of mortality using Cox regression were assessed. Results Three hundred seventy-five patients were included: 63 with diffuse cutaneous SSc, 279 with limited cutaneous SSc, and 33 with sine scleroderma. The SMR ratio was 1.88 (95% CI 1.46–1.97). The overall survival rates were 97.6% at 1 year, 93.4% at 3 years, 87.1% at 5 years, 77.9% at 10 years, and 61.3% at 15 years. Sixty-nine deaths were recorded. 46.4% were SSc related deaths secondary to interstitial lung disease (ILD) (34.4%), pulmonary hypertension (31.2%), and digestive tract involvement (18.8%). 53.6% were non-related to SSc: cardiovascular disorders (37.8%) and various infections (35.1%) largely distanced those from cancer (13.5%). Four significant independent predictive factors were identified: carbon monoxide diffusing capacity (DLCO) < 70% (HR=3.01; p=0.0053), C-reactive protein (CRP) >5 mg/l (HR=2.13; p=0.0174), cardiac involvement (HR=2.86; p=0.0012), and the fact of being male (HR=3.25; p=0.0004). Conclusion Long-term data confirmed high mortality of SSc. Male sex, DLCO <70%, cardiac involvement, and CRP> 5mg/l were identified as independent predictors of mortality.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of internal medicine · 2026 · Journal Article
Pallotti F, Mettler C, Papo M, Iudici M, et al.
Brain communications · 2025 · Journal Article
Miroglio R, Hocquel A, Ravel JM, Clément G, et al.
European journal of medical genetics · 2025 · Case Reports
Ducatel P, Verger A, Selton M, Renaud M, et al.
Journal of neurology · 2024 · Journal Article
Coly M, Adams D, Attarian S, Bouhour F, et al.
Orphanet journal of rare diseases · 2024 · Journal Article
Salort-Campana E, Solé G, Magot A, Tard C, et al.
European journal of neurology · 2023 · Multicenter Study
Berling E, Verebi C, Venturelli N, Vassilopoulos S, et al.
European journal of neurology · 2022 · Journal Article
Tard C, Salort-Campana E, Michaud M, Spinazzi M, et al.
Acta neuropathologica communications · 2021 · Journal Article
Biancalana V, Rendu J, Chaussenot A, Mecili H, et al.
Journal of neurology · 2020 · Journal Article
Kaminsky AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, et al.
European journal of internal medicine · 2020 · Letter
Michaud M, Bidouze L, Ancellin S, Catros F, et al.
Journal of neuromuscular diseases · 2020 · Journal Article
Michaud M, Stojkovic T, Maisonobe T, Behin A, et al.
European journal of internal medicine · 2016 · Letter
Michaud M, Moulis G, Puissant B, Cougoul P, et al.
The American journal of medicine · 2015 · Journal Article
Michaud M, Moulis G, Puissant B, Balardy L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
Orphanet journal of rare diseases · 2025 · Journal Article
Sanson B, Slioui A, Garcia J, Klouvi L, et al.
European journal of neurology · 2024 · Journal Article
Tard C, Bouhour F, Michaud M, Beltran S, et al.
Neurology · 2023 · Journal Article
Lefeuvre C, De Antonio M, Bouhour F, Tard C, et al.
Archives of cardiovascular diseases · 2026 · Journal Article
Fraix A, Algalarrondo V, Lairez O, Arnal M, et al.
European journal of neurology · 2024 · Journal Article
Tard C, Bouhour F, Michaud M, Beltran S, et al.
Frontiers in medicine · 2021 · Journal Article
Mahr A, Hachulla E, de Boysson H, Guerroui N, et al.
Annals of the rheumatic diseases · 2020 · Letter
Michaud M, Catros F, Ancellin S, Gaches F
Arthritis care & research · 2016 · Letter
Michaud M, Gaches F
Annals of the rheumatic diseases · 2020 · Letter
Michaud M, Catros F, Ancellin S, Gaches F
Arthritis care & research · 2016 · Letter
Michaud M, Gaches F
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
Rheumatology (Oxford, England) · 2023 · Journal Article
Gillard L, Pouchot J, Cohen-Aubart F, Koné-Paut I, et al.
European journal of neurology · 2026 · Journal Article
Theuriet J, Michaud M, Fargeot G, Labeyrie C, et al.
Journal of neurology · 2024 · Journal Article
Beloribi-Djefaflia S, Morales RJ, Fatehi F, Isapof A, et al.
La Revue de medecine interne · 2020 · Journal Article
Michaud M, Belmatoug N, Catros F, Ancellin S, et al.
Arthritis research & therapy · 2021 · Journal Article
De Almeida Chaves S, Porel T, Mounié M, Alric L, et al.
RMD open · 2026 · Journal Article
Idoate Lacasia J, Mourguet M, Villeneuve T, Cassard A, et al.
51ème Semaine Médicale de Lorraine Nancy 2016 : Pathologie neuro-musculaire ; quelles sont les indications d’un ENMG ? Qu’en attendre ?
Titre : 51ème Semaine Médicale de Lorraine Nancy 2016 : Pathologie neuro-musculaire ; quelles sont les indications d’un ENMG ? Qu’en attendre ? Intervenant : Dr Maud MICHAUD ------------------PROGRAMME MERCREDI 16 N
Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments
Abstract Background In 2017, a new treatment by nusinersen, an antisense oligonucleotide delivered by repeated intrathecal injections, became available for patients with spinal muscular atrophy (SMA), whereas clinical tr
Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments
Abstract Background In 2017, a new treatment by nusinersen, an antisense oligonucleotide delivered by repeated intrathecal injections, became available for patients with spinal muscular atrophy (SMA), whereas clinical tr
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
The Journal of rheumatology · 2021 · Journal Article
Toussirot E, Michaud M, Wendling D, Devauchelle V
European journal of internal medicine · 2020 · Letter
Michaud M, Catros F, Gaches F
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.
Journal of autoimmunity · 2018 · Journal Article
Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, et al.